龍磁科技(300835.SZ):終止出資600萬元認購合肥微晶定向增資擴股的3%股份事項
格隆匯 12 月 24日丨龍磁科技(300835.SZ)公佈,公司於2020年7月13日召開第五屆董事會第二次會議,審議通過了《關於對外投資參股的議案》,公司擬出資600萬元認購合肥微晶材料科技有限公司定向增資擴股的3%股份。該項對外投資事項不構成關聯交易,也不構成重大資產重組。
自籌劃此次對外投資事項以來,公司積極與相關方進行了溝通和協商。鑑於下游市場環境變化以及公司生產經營情況,綜合考慮各種相關因素,為維護上市公司及全體股東利益,經審慎考慮後,公司決定終止此次對外投資參股事項。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.